Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats Chronic Hepatitis C (CHC) Adult Patients. Sold as Pegasys. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Peginterferon Alfa-2a (sold as Pegasys), first approved Oct 16, 2002, with 9 new uses approved and 0 published complete response letters.
First approved: Oct 16, 2002
Applications: 1
New uses approved: 9
Complete response letters: 0
Medicare spending, 2025: $31.0M
First approved in the EU: Jun 20, 2002
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Pegasys S.C.Drugs with a new additional indication and a new dosage for the improvement of viremia in patients with chronic active hepatitis B. · Chugai Pharmaceutical Co., Ltd. · Sep 26, 2011
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
